Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zsila Sadighi is active.

Publication


Featured researches published by Zsila Sadighi.


Journal of Clinical Oncology | 2016

Long-Term Neurocognitive Functioning and Social Attainment in Adult Survivors of Pediatric CNS Tumors: Results From the St Jude Lifetime Cohort Study

Tara M. Brinkman; Matthew J. Krasin; Wei Liu; Gregory T. Armstrong; Rohit P. Ojha; Zsila Sadighi; Pankaj Gupta; Cara Kimberg; Deokumar Srivastava; Thomas E. Merchant; Amar Gajjar; Leslie L. Robison; Melissa M. Hudson; Kevin R. Krull

PURPOSE To assess the prevalence and severity of neurocognitive impairment in adult survivors of pediatric CNS tumors and to examine associated treatment exposures. PATIENTS AND METHODS Participants included 224 survivors of CNS tumors who were treated at St Jude Childrens Research Hospital (current median age [range], 26 years [19 to 53 years]; time from diagnosis, 18 years [11 to 42 years]) and completed neurocognitive testing. Information on cranial radiation therapy (CRT) doses and parameters of delivery were abstracted from medical records. The prevalence of severe impairment (ie, at least two standard deviations below normative mean) was compared across radiation treatment groups (no CRT, focal irradiation, craniospinal irradiation) using the χ(2) test. Log-binomial models were used to estimate risk ratios (RRs) and corresponding 95% CIs for severe impairment. RESULTS In multivariable models, craniospinal irradiation was associated with a 1.5- to threefold increased risk of severe impairment compared with no CRT (eg, intelligence: RR = 2.70; 95% CI, 1.37 to 5.34; memory: RR = 2.93; 95% CI, 1.69 to 5.08; executive function: RR = 1.74; 95% CI, 1.24 to 2.45). Seizures were associated with impaired academic performance (RR = 1.48; 95% CI, 1.02 to 2.14), attention (RR = 1.54; 95% CI, 1.12 to 2.13), and memory (RR = 1.44; 95% CI, 1.04 to 1.99). Hydrocephalus with shunt placement was associated with impaired intelligence (RR = 1.78; 95% CI, 1.12 to 2.82) and memory (RR = 1.42; 95% CI, 1.03 to 1.95). Differential follow-up time contributed to variability in prevalence estimates between survivors treated with older nonconformal and those treated with more contemporary conformal radiation therapy methods. Neurocognitive impairment was significantly associated with lower educational attainment, unemployment, and nonindependent living. CONCLUSION Survivors of pediatric CNS tumors are at risk of severe neurocognitive impairment in adulthood. The prevalence of severe impairment is greater than expected in the general population, even in the absence of CRT, and is associated with disrupted attainment of adult social milestones.


Journal of Child Neurology | 2013

Pilocytic Astrocytoma A Disease With Evolving Molecular Heterogeneity

Zsila Sadighi; John M. Slopis

Pilocytic astrocytoma, the most common pediatric brain tumor, is a clinically and molecularly heterogeneous disease that occurs most often in the cerebellum and hypothalamic and chiasmatic regions. Classically, pilocytic astrocytomas are driven by the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Recently described genetic aberrations involving this pathway are critical for tumorigenesis. Tandem duplication of 7q34 encodes BRAF and produces several KIAA1549-BRAF novel oncogenic fusions. Activating point mutations of BRAF, such as BRAF V600E, also lead to pilocytic astrocytoma. Loss of the NF1 gene allows hyperactivation of the oncogene KRAS. In this review, we discuss the current understanding of the novel molecular aberrations described in pilocytic astrocytomas and their clinical relevance for prognosis and treatment. The prognostic indications of these aberrations are discussed with regard to tumor location, tumor pathology, and patient age. A better understanding of the evolving molecular heterogeneity of pilocytic astrocytomas offers hope for developing molecularly targeted therapeutic armamentariums.


Neuro-oncology | 2014

Adult pilocytic astrocytomas: Clinical features and molecular analysis

Brett Theeler; Benjamin Ellezam; Zsila Sadighi; Vidya Mehta; M. Diep Tran; Adekunle M. Adesina; Janet M. Bruner; Vinay K. Puduvalli

BACKGROUND Adult pilocytic astrocytomas (PAs) are rare and have an aggressive clinical course compared with pediatric patients. Constitutive Ras/RAF/MAPK signaling appears to be an important oncogenic event in sporadic PA. We evaluated clinical data and molecular profiles of adult PAs at our institution. METHODS We identified 127 adult PAs in our institutional database. Cases with available tissue were tested for BRAF-KIAA1549 fusion/duplication (B-K fusion) by fluorescence in situ hybridization and submitted for mutation profiling using the Sequenom mutation profiling panel. Subgroup analyses were performed based on clinical and molecular data. RESULTS The majority of adult PAs are supratentorial. Twenty-two percent of cases had an initial pathologic diagnosis discordant with the diagnosis made at our institution. Recurrence was seen in 42% of cases, and 13% of patients died during follow-up. Adjuvant radiotherapy following surgical resection was associated with a statistically significant decrease in progression-free survival (P = .004). B-K fusion was identified in 20% (9 of 45) of patients but was not associated with outcome. No BRAF V600E mutations (0 of 40 tested) were found. CONCLUSION This was the largest single institution series of adult PA. A significant proportion of adult PAs follow an aggressive clinical course. Our results support a period of observation following biopsy or surgical resection. B-K fusion in adult PA does not influence outcome, and BRAF V600E mutation appears to be a very rare event. Further study of tumor biology and optimal treatment is needed, given a more aggressive clinical behavior.


Pediatric Blood & Cancer | 2016

Imaging Patterns and Outcome of Posterior Reversible Encephalopathy Syndrome During Childhood Cancer Treatment.

Raja B. Khan; Zsila Sadighi; Jennifer Zabrowski; Amar Gajjar; Sima Jeha

Diagnosis of posterior reversible encephalopathy syndrome (PRES) requires presence of headache, seizures, impaired vision, or altered mentation accompanied by specific imaging findings. We aimed to study long‐term clinical and radiologic outcome of PRES in children with cancer to augment limited available data.


Journal of Child Neurology | 2015

Diagnostic Clues to Human Herpesvirus 6 Encephalitis and Wernicke Encephalopathy After Pediatric Hematopoietic Cell Transplantation

Zsila Sadighi; Noah D. Sabin; Randall T. Hayden; Elizabeth Stewart; Asha Pillai

Human herpesvirus 6 (HHV6) encephalitis and Wernicke encephalopathy are treatable yet frequently undiagnosed causes of encephalopathy in pediatric recipients of allogeneic and autologous hematopoietic cell transplantation. Here we review representative cases of both conditions to highlight specific and relevant neurologic features that prompted effective diagnosis and treatment. Two patients with confusion accompanied by seizures, memory changes, or specific visual hallucinations and HHV6 detectable by polymerase chain reaction (PCR) in cerebrospinal fluid had improvement in viral load with ganciclovir or foscarnet treatment. Two patients had confusion, ataxia, or ocular changes and low serum thiamine levels, which resolved with parenteral thiamine. In all cases, definitive diagnosis and treatment were facilitated by a high index of suspicion and search for specific pathognomonic neurologic deficits accompanying the confusional state. It is critical to clinically differentiate these 2 conditions from other common neurologic syndromes occurring after transplant, allowing potentially improved patient outcomes by prompt diagnosis and effective treatment.


European Journal of Paediatric Neurology | 2014

Headache types, related morbidity, and quality of life in survivors of childhood acute lymphoblastic leukemia: A prospective cross sectional study

Zsila Sadighi; Kirsten K. Ness; Melissa M. Hudson; E. Brannon Morris; Davonna S. Ledet; Ching-Hon Pui; Scott C. Howard; Kevin R. Krull; Emily K. Browne; Debbie Crom; Pamela S. Hinds; Liang Zhu; Deokumar Srivastava; Raja B. Khan

BACKGROUND Increased headache prevalence was recently reported in survivors of childhood ALL. Headache sub types, related morbidity, and effect on quality of life has not been reported thus far. OBJECTIVE To study headache prevalence and type, related disability, and quality of life in a cohort of childhood acute lymphoblastic leukemia (ALL) survivors. METHODS Childhood ALL survivors in at least 1-year of remission and 5 years from diagnosis completed questionnaires and were evaluated by a neurologist. Disability was evaluated with Pediatric Migraine Disability Assessment scale and the Short Form-36 Health Survey assessed quality of life. RESULTS Thirty nine of 72 (54%) females and 37 of 90 (41%) males reported headaches. Median time from ALL diagnosis to first headache was 5.2 years and median age at headache onset was 10.1 years in 76 participants with headache. Migraine headaches were diagnosed in 51 (31%) and episodic tension-type headaches in 49 (30%); migraine and tension-type headaches co-existed in 24 (15%) and 18 (11%) participants had chronic daily headaches. Fatigue was associated with migraine headache while hypertension and female gender associated with tension type headache. Headache-related disability was mild in 22 (29%), moderate in 7 (9%), and severe in 5 (7%) survivors, and was absent in the remaining 42 (55%) survivors with headache. Both migraine and tension type headaches associated with reduced mental component scores, while headache related disability associated with a reduced physical component scores. CONCLUSIONS Headaches are common in ALL survivors but only a minority has significant disability or impairment of quality of life.


Pediatric Blood & Cancer | 2018

Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis

Zsila Sadighi; Elizabeth Curtis; Jennifer Zabrowksi; Catherine A. Billups; Amar Gajjar; Raja B. Khan; Ibrahim Qaddoumi

The neurologic outcomes of low‐grade gliomas (LGGs) according to tumor location and duration of presenting symptoms remain poorly characterized in children.


Neuro-Oncology Practice | 2018

Profound hearing loss following surgery in pediatric patients with posterior fossa low-grade glioma

Yahya Ghazwani; Ibrahim Qaddoumi; Johnnie K. Bass; Shengjie Wu; Jason Chiang; Frederick A. Boop; Amar Gajjar; Zsila Sadighi

Background Hearing loss may occur in patients with posterior fossa low-grade glioma who undergo surgery. Methods We retrospectively reviewed 217 patients with posterior fossa low-grade glioma, including 115 for whom results of hearing tests performed after surgery and before chemotherapy or radiation therapy were available. We explored the association of UHL with age at diagnosis, sex, race, tumor location, extent of resection, posterior fossa syndrome, ventriculoperitoneal shunt placement, and histology. Results Of the 115 patients, 15 (13.0%: 11 male, 6 black, 8 white, 1 multiracial; median age 7 years [range, 1.3-17.2 years]) had profound UHL after surgery alone or before receiving ototoxic therapy. Median age at tumor diagnosis was 6.8 years (range, 0.7-14.1 years), and median age at surgery was 6.8 years (range, 0.7-14.1 years). Patients with UHL had pathology characteristic of pilocytic astrocytoma (n = 10), ganglioglioma (n = 4), or low-grade astrocytoma (n = 1). Of these 15 patients, 4 underwent biopsy, 1 underwent gross total resection, 1 underwent near-total resection, and 9 underwent subtotal resection. UHL was more frequent in black patients than in white patients (OR 7.3, P = .007) and less frequent in patients who underwent gross total resection or near-total resection than in those who underwent subtotal resection (OR 0.11, P = .02). Conclusions Children undergoing surgery for posterior fossa low-grade glioma are at risk for UHL, which may be related to race or extent of resection. These patients should receive postoperative audiologic testing, as earlier intervention may improve outcomes.


Journal of Child Neurology | 2017

The Complex Diagnostic Challenge in Children With Non–Central Nervous System Cancer and Cerebellar Mutism

Kathleen J. Helton; Amy L. Patterson; Raja B. Khan; Zsila Sadighi

Multiple etiologies should be considered in the differential diagnosis of immunocompromised patients with non–central nervous system cancer and viral infections who develop mutism. Acute cerebellitis, caused by infections or by neurotoxicity resulting from chemotherapy; paraneoplastic cerebellar degeneration; atypical posterior reversible encephalopathy syndrome; and acute disseminated encephalomyelitis may all cause mutism in such patients. This condition warrants prompt recognition and may require treatment with immunotherapy, as it may be an immune-mediated process. We present 2 patients with leukemia and viral illness who developed cerebellar mutism in the setting of acute cerebellitis and responded to immunotherapy, suggesting that the condition involved a parainfectious immune-mediated response.


Neuro-oncology | 2018

LGG-30. EVALUATING PEDIATRIC SPINAL LOW-GRADE GLIOMAS-A 30-YEAR RETROSPECTIVE ANALYSIS

Steven Carey; Zsila Sadighi; Shengjie Wu; Jason Chiang; Yahya Ghazwani; Sahaja Acharya; F.A. Boop; Amar Gajjar; Ibrahim Qaddoumi

Collaboration


Dive into the Zsila Sadighi's collaboration.

Top Co-Authors

Avatar

Raja B. Khan

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Amar Gajjar

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Jennifer Zabrowski

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Thomas E. Merchant

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Frederick A. Boop

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Ibrahim Qaddoumi

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Kevin R. Krull

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Melissa M. Hudson

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Tara M. Brinkman

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Alberto Broniscer

St. Jude Children's Research Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge